New York, New York--(Newsfile Corp. - December 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ ...

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 5, 2026 [3]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary launch steps, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

New York, New York--(Newsfile Corp. - December 16, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to alleged violations of federal securities laws related to misleading statements about the launch of the Inspire V device and its market demand [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [2]. - Investors who suffered losses in Inspire Medical are encouraged to contact the firm to discuss their legal options [1]. Group 2: Company Performance and Issues - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays due to incomplete training and onboarding at treatment centers [5]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, affecting the ability to bill for procedures [5]. - Inspire reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [6]. Group 3: Market Impact - Following the announcement of these issues, Inspire Medical's stock price dropped over 32% in one day, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [6].

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

New York, New York--(Newsfile Corp. - December 15, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ ...

Core Viewpoint - Wasatch Global Investors reported that US small-cap equities experienced a strong rally in Q3 2025, supported by the Federal Reserve's interest rate cut, but the Wasatch Small Cap Growth Strategy fund underperformed, ending down -3.17% compared to a 12.19% gain for the Russell 2000 Growth Index [1]. Company Summary - Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company focused on minimally invasive solutions for obstructive sleep apnea, with a one-month return of 53.98% but a 52-week loss of 30.79%, closing at $130.68 per share and a market capitalization of $3.865 billion as of December 12, 2025 [2]. - Inspire Medical Systems reported revenue of $224.5 million in Q3 2025, marking a 10% increase from Q3 2024 [4]. Investment Decisions - The Wasatch Small Cap Growth Strategy decided to sell its position in Inspire Medical Systems during Q3 2025 due to management downgrading full-year guidance and concerns about the execution of the Inspire V system rollout, as well as potential market impacts from GLP-1 drugs [3]. - Inspire Medical Systems is not among the 30 most popular stocks among hedge funds, with 48 hedge fund portfolios holding the stock at the end of Q3 2025, an increase from 34 in the previous quarter [4].

NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) 453-890 ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit claims are based on Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in Inspire stock. The case is pending in the U.S. District Court for the District of Minnesota [3]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," leading to a reduction in 2025 earnings per share guidance by over 80%. This was attributed to undisclosed factors affecting the rollout and weak demand due to excess inventory of older devices [7][8]. Stock Price Impact - Following the announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].